Extensive cystic fibrosis transmembrane conductance regulator gene analysis by denaturing gradient gel electrophoresis, denaturing high-performance liquid chromatography, and DNA sequencing ...

The cystic fibrosis transmembrane conductance regulator has been studied for years but the new efforts have yielded important insights.

Here's what cystic fibrosis is, what causes it and how it's usually treated once it has been diagnosed. Start the day smarter. Get all the news you need in your inbox each morning. What is ...

Licensed for use in the UK in March, Alyftrek will now be immediately funded by the NHS in England. This rapid timeline demonstrates NICE's commitment to getting breakthrough treatments to patients ...

Patients naïve to cystic fibrosis transmembrane conductance regulator modulators had comparable improvements to patients with prior exposure.

Individuals with cystic fibrosis or CFTR gene variants have a 3-fold higher risk of developing pancreatic cancer after 50 years of age.

Cystic fibrosis (CF) is a genetic disorder that causes the body to produce thick, sticky mucus that builds up mainly in the ...

A mutation in the cystic fibrosis transmembrane conductance regulator (CFTR) gene causes an excessive build-up of mucus in the lungs and dysregulated airway inflammation, making those with the ...

Cystic fibrosis (CF) is a genetic condition that affects the lungs, pancreas and other organs, caused by variations on the cystic fibrosis transmembrane conductance regulator (CFTR) gene.

NHS patients in England with cystic fibrosis will be among the first in Europe to access a new treatment for their condition, ...

A UB-led research team has developed molecules that could help unclog thick, sticky mucus from the lungs of people suffering from cystic fibrosis. The chronic disease is caused by a defective protein ...

Cystic fibrosis transmembrane conductance regulator (CFTR) modulators were a breakthrough for cystic fibrosis, improving the movement of chloride and water and moistening mucus secretions. But ...